Apolipoprotein E ε4 is superior to apolipoprotein E ε2 in predicting cognitive scores over 30 months

Figures & data

Table 1 Comparison of 178 Apo E ε4 negative subjects with 109 Apo E ε4 positive subjects

Parameter	Apo E Neg	Apo E Pos	P/BonP/DFM
Mean age	80.6 ± 6.7	78.5 ± 5.9	0.0116/NA/2.6%
Female (%)	48.3	56.9	0.16
Living alone (%)	30.3	30.2	0.99
Married (%)	53.9	56.9	0.83
Education, years	9.8 ± 2.0	10.0 ± 1.8	0.33/NA/2.0%
Dementia at baseline (%)	51.7	58.7	0.249
Diabetes at baseline (%)	25.8	10.1	0.001/0.01 n = 10
Atrial fibrillation at baseline (%)	11.8	9.2	0.31
Weight, kg	70.1 + 16.3	67.8 ± 14.4	0.175/3.3%
BMI	26.8 ± 5.3	25.8 ± 4.5	0.195/3.7%
CIRS	7.77 ± 2.13	6.57 ± 2.41	0.007/0.07/15.4%
IADL-1 (0–22)	14.2 ± 5.0	14.4 ± 5.7	0.543/NA/1.4%
MMSE-1 (0–30)	23.3 ± 4.6	22.3 ± 6.0	0.061/0.61/4.3%
MoCA-1 (0–30)	18.0 ± 5.8	16.5 ± 6.1	0.071/0.671/8.3%
ACE-R (0–100)	66.8 ± 16.5	63.9 ± 18.1	0.320/NA/4.3%
DI-1 (0, best; 21, worst)	3.15 ± 2.00	3.90 ± 1.81	0.041/0.41/23.8%
Six months IADL-6	13.8 ± 5.5	13.7 ± 5.9	0.920/NA/0.7%
MMSE-6	23.4 ± 4.9	21.7 ± 5.3	0.01/0.05/7.3%
MoCA-6	17.8 ± 6.0	16.1 ± 6.2	0.048/0.24/9.6%
ACE-6	69.1 ± 13.7	65.4 ± 14.5	0.0636/0.32/5.3%
DI-6	3.34 ± 2.07	4.27 ± 1.88	0.013/0.065/27.8%
12 months IADL-12	13.3 ± 5.9	13.0 ± 5.7	0.527/NA/2.2%
MMSE-12	22.9 ± 5.2	21.9 ± 5.6	0.0081/0.040/4.4%
MoCA-12	17.9 ± 6.7	16.0 ± 6.2	0.032/0.16/10.6%
ACE-12	69.6 ± 15.4	64.6 ± 15.7	0.032/0.16/7.2%
DI-12	3.32 ± 2.25	4.36 ± 1.94	0.0053/0.026/31.3%
18 months IADL-18	12.0 ± 6.5	11.4 ± 5.5	0.523/NA/5.0%
MMSE-18	22.1 ± 5.4	20.2 ± 6.4	0.064/0.32/8.6%
MoCA-18	17.5 ± 6.4	14.8 ± 6.5	0.017/0.085/15.4%
ACE-18	66.5 ± 15.4	61.6 ± 18.0	0.10/0.50/7.4%
DI-18	3.83 ± 2.30	4.82 ± 2.12	0.007/0.035/25.8%
24 months IADL-24	11.6 ± 6.5	10.2 ± 6.1	0.245/NA/12.1%
MMSE-24	22.6 ± 6.7	20.6 ± 6.2	0.040/0.20/8.8%
MoCA-24	17.7 ± 7.1	15.6 ± 7.5	0.117/0.58/11.9%
ACE-24	68.9 ± 17.8	60.7 ± 18.5	0.023/0.11/11.9%
DI-24	3.36 ± 2.35	4.46 ± 2.40	0.018/0.09/32.7%
30 months IADL-30	11.3 ± 6.5	10.2 ± 5.8	0.443/NA/9.3%
MMSE-30	22.8 ± 5.8	19.2 ± 6.5	0.032/0.16/15.8%
MoCA-30	17.4 ± 6.5	15.2 ± 7.6	0.244/NA/12.6%
ACE-30	69.6 ± 11.9	60.2 ± 21.2	0.15/NA/13.5%
DI-30	3.63 ± 2.20	4.79 ± 2.24	0.034/0.17/34.5%

Notes: The suffix “1” denotes baseline, “6” denotes 6 months, “12” denotes 12 months, “18” denotes 18 months. Significant differences are depicted in bold. DFM calculated as mean for Apo E-negative minus mean Apo E-positive/mean Apo E-negative. Bonferroni correction was made for the five scores at each point in time and is designated as Bon No Bon P. P-values for weight, kg and BMI.

Abbreviations: Apo E Neg, apolipoprotein E-negative; Apo E Pos, apolipoprotein E-positive; NA, not applicable; DFM, difference between means; ACE, Addenbrooke Cognitive Examination; BMI, body mass index; CIRS, Cumulative Illness Rating Scale; DFM, percentage difference between the means of the two groups; DI, delirium index; IADL, Nottingham instrumental activities of daily living; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; P, P-value; Bon, bonferroni.